Autolus is here to support you as you navigate the AUCATZYL treatment process
Our aim is to help you optimise outcomes for adult patients with R/R B-ALL by offering support at every stage
-
InformationAccessible guidance on AUCATZYL including information on assessing patient suitability
-
EducationResources to support understanding of treatment for you and your patients
-
Ongoing supportOngoing engagement with our team throughout the treatment journey and beyond
Our team is here to answer your questions and provide the resources most relevant to you
-
Jessica ColesCell Therapy Account Executive, UK -
Claire DickinsonCell Therapy Account Executive, UK
You can get in touch with Jessica or Claire by emailing UKCommercial@autolus.com
Science is at the centre of everything we do
Autolus is a CAR T-cell therapy company dedicated to advancing treatments for patients with cancer and autoimmune diseases.
Founded in 2014 from Dr Martin Pule’s laboratory at University College London, our work builds on his pioneering cell-programming technology that led to the development of AUCATZYL.
Process and administration
Learn more about tumour-guided split dosing and how to administer AUCATZYL.
Stay updated
Sign up to receive the latest news and product updates from Autolus.
By clicking ‘Receive key updates’ you’re confirming that you agree with our Terms and conditions.
Aucatzyl is indicated for the treatment of adult patients (≥18 years) with relapsed or refractory B cell precursor acute lymphoblastic leukaemia.1
NICE recommends AUCATZYL to treat relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in people aged ≥26 years in England, Wales and Northern Ireland.2,3
B-ALL=B-cell precursor acute lymphoblastic leukaemia, CAR=chimeric antigen receptor, NICE=National Institute for Health and Care Excellence, R/R=relapsed/refractory.
Summary of Product Characteristics, Aucatzyl 2025.
NICE. Obecabtagene autoleucel for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemia. Issued December 2025. Accessed February 2026. https://www.nice.org.uk/guidance/ta1116/resources/obecabtagene-autoleucel-for-treating-relapsed-or-refractory-bcell-precursor-acute-lymphoblastic-leukaemia-pdf-2973530453903557.
AWTTC. Obecabtagene autoleucel (Aucatzyl®). Issued November 2025. Accessed February 2026. https://awttc.nhs.wales/accessing-medicines/medicine-recommendations/obecabtagene-autoleucel-aucatzyl/.
